GLP-1 News — Week of July 27, 2026
The GLP-1 stories that mattered this week — what happened, and what each one means for you if you're using or considering these medications. Every story links to its primary source, and nothing here is influenced by advertisers.
CMS spells out exactly who can get Wegovy, Zepbound, and Foundayo for $50 under Medicare GLP-1 Bridge
CMS released detailed guidance for Medicare Part D plans on how to run the new Medicare GLP-1 Bridge, effective July 1, 2026. The agency clarified that all formulations of Wegovy, all formulations of Foundayo (orforglipron), and the Zepbound KwikPen can be covered at about $50 per month for adults with obesity (BMI of at least 30) plus specific conditions like certain types of heart failure, resistant hypertension, or stage 3a or worse chronic kidney disease. The guidance also notes that uses already covered under standard Part D, such as Wegovy for cardiovascular risk reduction or Zepbound for obstructive sleep apnea, are handled outside the Bridge rules. (2026-07-15)
What this means for you: If you are on Medicare and have obesity plus one of the listed conditions, you may now qualify for Wegovy, Zepbound KwikPen, or Foundayo at a far lower out of pocket cost, even if your plan previously excluded these drugs. To make this real, you need to confirm your plan is participating, check that your diagnoses match CMS criteria, and work with your prescriber to document eligibility using the exact language plans now follow.
Source: CMS
Related on Metabolic Ledger: /cost/medicare-glp1-coverage
Early Medicare GLP-1 Bridge data show many older adults choosing injectable Wegovy and Zepbound
Reuters reporting on the first weeks of the Medicare GLP-1 Bridge finds that many eligible older adults are opting for injectable obesity drugs such as Wegovy and Zepbound rather than waiting for orals. Doctors and analysts describe strong pent-up demand from Medicare patients who could not previously afford these medicines, and note that concerns about injection discomfort are often outweighed by expectations of greater effectiveness. The piece underscores that this demand is emerging even as plan participation and access logistics are still being worked out. (2026-07-22)
What this means for you: If you are a Medicare beneficiary who meets Bridge criteria, you should not assume that only pills will be available or suitable for you, because injectables are being widely used in the program. It is worth discussing with your clinician whether an injectable or oral GLP-1 makes more sense for your health history and comfort, and double-checking with your Part D plan what they will actually cover under the Bridge today.
Source: Reuters via Investing.com
Related on Metabolic Ledger: /cost/medicare-glp1-coverage
Consumer guide breaks down how to actually get GLP-1 drugs for $50 on Medicare, and the catches
Kiplinger published a step by step explainer on the Medicare GLP-1 Bridge that translates CMS policy into practical instructions for patients. The article emphasizes that eligible Medicare beneficiaries in participating Part D plans can access Wegovy, Zepbound KwikPen, or Foundayo for a flat $50 monthly copay if they meet body mass index and comorbidity rules, but also stresses that not every plan participates and that the program is time limited. It highlights the need to verify plan participation, understand prior authorization steps, and plan for what happens when the demonstration ends. (2026-07-30)
What this means for you: If you or a family member are on Medicare and trying to figure out whether you can realistically get a $50 GLP-1 prescription, this coverage gives you concrete questions to ask your plan and doctor rather than relying on headlines. It does not change eligibility, but it can help you navigate the fine print, avoid surprises, and prepare for possible cost changes after the Bridge period.
Source: Kiplinger
Related on Metabolic Ledger: /cost/medicare-glp1-coverage
Study finds compounded Ozempic and Zepbound still widely sold despite official shortage ending
A JAMA Health Forum study, summarized by Drugs.com, used a secret shopper method to show that clinics and spas in at least two states continue to market and sell compounded semaglutide and tirzepatide products for weight loss even after the FDA declared drug shortages resolved. The researchers documented offers of compounded versions labeled as alternatives to Ozempic, Wegovy, Mounjaro, or Zepbound, often through nontraditional channels and without clear evidence of clinical need. This persistence raises concerns about whether FDA and state regulators are effectively curbing unnecessary compounding of these drugs from bulk ingredients. (2026-07-21)
What this means for you: If you are considering cheaper compounded GLP-1 products, you should know that regulators already question the need and safety of many of these offerings, and enforcement is tightening even though they remain easy to find. You may face sudden discontinuations or quality variability, so it is important to verify the pharmacy, talk with your clinician, and have a plan to switch to an FDA approved product if compounded options are restricted or stopped.
Source: Drugs.com
Related on Metabolic Ledger: /regulatory/where-to-get-compounded-glp1-2026